Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | oHSV2-PD-L1/CD3-BsAb |
Synonyms | |
Therapy Description |
oHSV2-PD-L1/CD3-BsAb is an oncolytic virus derived from herpes simplex virus type 2 and engineered to express a bispecific antibody targeting both CD274 (PD-L1) and CD3, which may increase T-cell activation and decrease tumor growth (PMID: 35272497). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
oHSV2-PD-L1/CD3-BsAb | oHSV2-PD-L1/CD3-BsAb is an oncolytic virus derived from herpes simplex virus type 2 and engineered to express a bispecific antibody targeting both CD274 (PD-L1) and CD3, which may increase T-cell activation and decrease tumor growth (PMID: 35272497). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05938296 | Phase I | oHSV2-PD-L1/CD3-BsAb | oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection | Recruiting | USA | 0 |